InvestorsHub Logo
Followers 52
Posts 9070
Boards Moderated 1
Alias Born 10/25/2007

Re: None

Saturday, 12/16/2023 12:09:59 AM

Saturday, December 16, 2023 12:09:59 AM

Post# of 13431
Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data For MRNA-1345, The Company’s Investigational Respiratory Syncytial Virus (RSV) Vaccine

Moderna has submitted marketing authorizations globally for mRNA-1345 and continues to prepare for an expected 2024 marketing launch

https://www.nejm.org/doi/full/10.1056/NEJMoa2307079
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRNA News